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Abstract
It is often stated that only a small proportion of adult cancer patients participate in clinical trials.
This is said to be a bad thing, with calls for more trials to include more patients. Here I argue that
whether or not greater accrual to clinical trials would be a good thing depends on the trials we
conduct. The vast majority of clinical trials in cancer are currently early phase trials, and most do
not lead to further studies even if they have encouraging results. The key metric is thus not the
number of patients on clinical trials, but the number on the sort of large, randomized, Phase III trials
that can be used as a basis for clinical decisions. I also address two important barriers to greater
clinical trial participation. The first barrier is financial: clinical research has long been the poor
cousin of basic research, with perhaps no more than a nickel in the cancer research dollar going to
clinical research. The second barrier is regulatory: clinical research has become so overburdened
by regulation that it takes years to initiate a trial, and dedicated staff just to deal with the paperwork
once the trial starts. This not only adds significantly to the costs of clinical research, but scares many
young investigators away. It has been estimated that nearly half of all US-sponsored trials are being
conducted abroad, and it is plausible that excessive regulation is at least partly responsible. That
statistic should serve as a wake-up call to the US clinical research community to implement the
recommendations of the now decade-old report of National Cancer Institute Clinical Trials
Program Review Group, which largely center around simplifying trials and streamlining trial
procedures.
Background
In a recent paper in Trials, Wright et al examined divergent
understandings of what constitutes a clinical trial in
oncology[1]. The motivation for their study was to inform
statistics and debates about clinical trial participation. It is
often stated that only a small proportion of adult cancer
patients participate in clinical trials – less than 5% being
a typical estimate[2] – and that this needs to increase.
Wright et al argue that it might be difficult to define
exactly how many patients are or should be on clinical tri-
als if there is no clear agreement on what qualifies as a
trial.
In this editorial, I will discuss two related questions. First,
should we want more cancer patients on clinical trials?
Second, what are the practical steps we should take to
ensure better clinical trial accrual? My thoughts on these
questions are very much a personal perspective from my
own experience of working in a major cancer center in the
USA. Although other authors have drawn similar conclu-
sions[3,4], it is for the reader to judge the degree to which
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they are applicable to other countries, or to non-academic
settings.
Discussion
Do we want more cancer patients on clinical trials?
It is often assumed that higher clinical trial accrual would
automatically be a good thing; certainly for medical
research and future patients, but likely also for those cur-
rently being treated for cancer. But whether or not greater
accrual to clinical trials would be of benefit depends on
the trials we conduct. Putting more cancer patients on tri-
als is just a means to an end – better data to inform clinical
care – and we have to keep the end primary. As Doug Alt-
man remarked, we do not need more research, "we need
less research, better research, research done for the right
reasons"[5].
Unfortunately, all too many cancer clinical trials are done
for the wrong reasons. Ian Tannock and colleagues at the
Princess Margaret Hospital in Toronto recently surveyed
investigators of Phase II trials. The purpose of Phase II tri-
als is to determine whether there is sufficient preliminary
evidence of efficacy to warrant a large, randomized Phase
III trial as a definitive test of whether a cancer agent is of
value. Tannock contacted investigators of 36 Phase II trials
with promising results and found that only 10 intended to
conduct a subsequent Phase III. He concluded that "the
real purpose of many phase II trials may be to legitimize
the use of nonapproved compounds, or to enhance the
investigators' CVs"[6].
I recently estimated that there are at least 12 times as many
early phase trials in cancer as randomized Phase III tri-
als[7]. Such trials have their place – indeed, they are essen-
tial to drug development – but they cannot usually help
an oncologist make a decision about clinical care. "Get-
ting more patients on trials" will therefore not improve
cancer outcomes if the trials are all early phase, and espe-
cially if the trials are not intended to prompt further
research. The key metric, I suggest, is not the number of
patients on clinical trials, but the number on the sort of
large, randomized, Phase III trials that can be used as a
basis for clinical decisions[8]. Not all Phase III trials will
be good ones, and not all will ask important questions,
but if we had to choose one number to reflect our
progress, the number of patients on Phase III trials would
be it.
How do we get more patients on clinical trials?
There are many barriers to increasing clinical trial enroll-
ment; I will focus on just two, financing and regulation.
With respect to funding, I have little doubt that clinical
research is the poor relation in cancer research. For exam-
ple, the funding of co-operative groups, which organize
most of the large randomized trials in cancer, has been flat
for years and constitutes only $150 m of the National
Cancer Institute's $5 bn budget[9]
Any attempts to expand clinical trials in cancer will also
need to address the issue of regulatory burden. Dilts et al
have estimated that initiating a clinical trial through
CALGB, one of the major US groups organizing large can-
cer trials, typically requires more than two years and over
370 separate steps[10]. Even a small, single-center trial
can be a huge burden to initiate, requiring review by mul-
tiple clinical, scientific and ethical review committees.
Many investigators describe the approval process for clin-
ical trials as "traumatic" or "nightmarish" and I have met
several young, smart, savvy investigators who have told
me that they would love to do clinical trials, but "can't
face" going through the approval process and, as a result,
are going to stick to laboratory work and retrospective
studies. Of course, it is only once a trial gets going that the
regulatory burden really kicks in. Paperwork and docu-
mentation requirements for a typical cancer trial are so
intense that, at our hospital, we typically allocate one full-
time research assistant for 50 trial patients per year. In
other words, it takes about an entire work week to manage
the paperwork of a single clinical trial patient. It is true
that, in some cases, one might lay at least some of the
blame for excessive paperwork on poor design and unnec-
essary data collection; nonetheless, one cannot help but
speculate as to how much researcher time might be freed
up were regulatory requirements to be liberalized.
The National Cancer Institute is not unaware of these
problems. A "Clinical Trials Program Review Group" has
put together an excellent report[11], some of my favorite
quotes from which are given in table 1. But note one
thing: the report is over 10 years old. It is all very well for
leading experts to call for simplifying the informed con-
sent process, reducing eligibility criteria and limiting the
number of endpoints, but it is as good as useless if these
recommendations are not taken up by those who write or
review protocols.
Conclusion
The most commonly diagnosed cancer in men is prostate
cancer. Yet at the time of writing there have been no ade-
quate trials comparing the two major treatment
approaches, radiotherapy and surgery[12]. It is obvious to
me that we should prefer a single 10,000 patient rand-
omized trial comparing primary treatment for prostate
cancer to having 20,000 patients join the sort of early
phase trials that typically go nowhere. What we need is
not more patients on clinical trials, but more patients on
the right sorts of trials.
Giving the barriers I have discussed above, getting these
trials done will not be straightforward. Indeed, many US-Trials 2008, 9:31 http://www.trialsjournal.com/content/9/1/31
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based clinical researchers have simply given up and are
conducting research abroad: one estimate is that about
45% of US-sponsored trials are currently being conducted
overseas[13]. This statistic should serve as a wake-up call
to the cancer research community: those billions of dol-
lars we spend on laboratory research will only have been
a good investment if new therapies or tests discovered in
the laboratory turn out to improve patient care, and that
will only happen if we do the right clinical trials.
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Table 1: 
Excerpts from the Report of the National Cancer Institute Clinical Trials Program Review Group August 26, 1997
Informed Consent:
It is the opinion of the Review Group that the informed consent process is onerous and overly cautious. In many cases it has become a disclaimer 
for institutions rather than information for the participant. As a result, true informed consent is not being obtained and the informed process itself 
may be inappropriately deterring individuals from participating in clinical trials ... Simplified informed consent documents will assist both trial 
participants and physicians ... and are essential.
Trial eligibility criteria
[There are] far too many exclusion criteria in the current clinical trials system. Potential enrollees are disqualified for seemingly arbitrary reasons 
from trials for which they would otherwise qualify ... The eligibility criteria for all cancer clinical trials should be simplified in order to require 
minimal input at the time of registration of individuals, and to substantially reduce the workload for the individual conducting the registration.
Protocol development
Rapid protocol development is critical to the ability to implement new ideas and concepts in an expeditious fashion. Groups should develop a 
common algorithm for protocol development in order to minimize the time necessary to develop and obtain a letter of intent or concept to NCI 
for consideration and review.
Data collection
Data collection should be reduced so that only data pertinent to the study endpoints and patient safety are accrued. In addition, NCI-funded efforts 
should include some large, uncomplicated trials in common cancers with minimal data requirements and accrual goals large enough to establish 
treatment differences definitively.
Use of information technology to facilitate clinical trials management
Forms required for trial randomization do not take advantage of computer systems creating even more work for the investigator. The resulting 
enrollment system is slow, inefficient and costly. The money that could be saved through a more uniform and streamlined process could be used to 
enroll more patients in trials. A single informatics system for the NCI, all cancer centers, and all cooperative groups is important to the success of 
the clinical trials program.